Press Releases

08.20.2021

XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

08.16.2021

Pfizer Prices $1.0 Billion Sustainability Bond

08.16.2021

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

08.13.2021

U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine

08.12.2021

VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease

08.04.2021

Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata

07.28.2021

PFIZER REPORTS SECOND-QUARTER 2021 RESULTS

07.23.2021

Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.

07.22.2021

Arvinas And Pfizer Announce Global Collaboration To Develop And Commercialize Protac® Protein Degrader Arv-471

07.22.2021

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471

07.21.2021

Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings

07.21.2021

Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa